Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Micron and Anadarko Petroleum, have not done well during the last 12 months ending in October due to various reasons. Nevertheless, the data show elite investors’ consensus picks have done well on average. The top 30 S&P 500 stocks among hedge funds at the end of September 2014 yielded an average return of 9.5% during the last four quarters ending in October and sixty three percent of these 30 stocks outperformed the market. S&P 500 Index returned only 5.2% during the same period and less than 49% of its constituents managed to beat this return. Because their consensus picks have done well, we pay attention to what elite funds think before doing extensive research on a stock. In this article, we take a closer look at OvaScience Inc (NASDAQ:OVAS) from the perspective of those elite funds.
As OvaScience Inc (NASDAQ:OVAS)’s stock plunged by 69% in the third quarter, it has experienced a decrease in support from the world’s most elite money managers. However, the level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Bel Fuse, Inc. (NASDAQ:BELFB), Independence Realty Trust Inc (NYSEMKT:IRT), and Safe Bulkers, Inc. (NYSE:SB) to gather more data points.
Follow Tempest Therapeutics Inc. (NASDAQ:TPST)
Follow Tempest Therapeutics Inc. (NASDAQ:TPST)
In the eyes of most market participants, hedge funds are seen as worthless, outdated investment tools of the past. While there are over 8000 funds trading at the moment, Our researchers hone in on the bigwigs of this group, about 700 funds. These hedge fund managers watch over most of all hedge funds’ total capital, and by watching their matchless equity investments, Insider Monkey has found several investment strategies that have historically exceeded the market. Insider Monkey’s small-cap hedge fund strategy outrun the S&P 500 index by 12 percentage points a year for a decade in their back tests.
With all of this in mind, we’re going to take a glance at the new action surrounding OvaScience Inc (NASDAQ:OVAS).
How have hedgies been trading OvaScience Inc (NASDAQ:OVAS)?
Heading into Q4, a total of 13 of the hedge funds tracked by Insider Monkey held long positions in this stock, a decline of 7% from the second quarter. With the smart money’s positions undergoing their usual ebb and flow, there exists a few key hedge fund managers who were boosting their stakes considerably (or already accumulated large positions).
When looking at the institutional investors followed by Insider Monkey, Adage Capital Management, managed by Phill Gross and Robert Atchinson, holds the number one position in OvaScience Inc (NASDAQ:OVAS). Adage Capital Management has an $18.9 million position in the stock, comprising 0.1% of its 13F portfolio. Coming in second is Orbis Investment Management, managed by William B. Gray, which holds a $17.7 million position; the fund has 0.2% of its 13F portfolio invested in the stock. Other members of the smart money that are bullish consist of Hal Mintz’s Sabby Capital and Bihua Chen’s Cormorant Asset Management.
